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Abstract
Both thromboxane (TX) A2 and 8-epi prostaglandin (PG) F2K have been reported to stimulate mitogenesis of vascular
smooth muscle (SM) in a number of species. However, TXA2 and 8-epiPGF2K mediated mitogenic signalling has not been
studied in detail in human vascular SM. Thus, using the human uterine ULTR cell line as a model, we investigated TXA2
receptor (TP) mediated mitogenic signalling in cultured human vascular SMCs. Both the TP agonist U46619 and 8-epiPGF2K
elicited time and concentration dependent activation of the extracellular signal regulated kinase (ERK)s and c-Jun
N-terminal kinase (JNK)s in ULTR cells. Whereas the TP antagonist SQ29548 abolished U46619 mediated signalling, it only
partially inhibited 8-epiPGF2K mediated ERK and JNK activation in ULTR cells. Both U46619 and 8-epiPGF2K induced
ERK activations were inhibited by the protein kinase (PK) C, PKA and phosphoinositide 3-kinase inhibitors GF109203X,
H-89 and wortmannin, respectively, but were unaffected by pertussis toxin. In addition, U46619 mediated ERK activation in
ULTR cells involves transactivation of the epidermal growth factor (EGF) receptor. In humans, TXA2 signals through two
distinct TP isoforms. In investigating the involvement of the TP isoforms in mitogenic signalling, both TPK and TPL
independently directed U46619 and 8-epiPGF2K mediated ERK and JNK activation in human embryonic kidney (HEK) 293
cells over-expressing the individual TP isoforms. However, in contrast to that which occurred in ULTR cells, SQ29548
abolished 8-epiPGF2K mediated ERK and JNK activation through both TPK and TPL in HEK 293 cells providing further
evidence that 8-epiPGF2K may signal through alternative receptors, in addition to the TPs, in human uterine ULTR
cells. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
The prostanoid thromboxane A2 (TXA2) mediates
a number of responses in smooth muscle (SM) cells
including constriction of aortic and uterine SM [1]
and stimulation of mitogenic/hypertrophic responses
in vascular SM [2]. In humans, molecular cloning has
identi¢ed two receptors for TXA2, termed TXA2 re-
ceptor (TP)K and TPL, which are encoded by a single
TP gene but which arise by di¡erential splicing and
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which di¡er exclusively in their carboxyl terminal tail
regions [3^5]. Whereas the physiologic signi¢cance
for the existence for two TP receptors in humans,
but not in other species, is currently unknown, di¡er-
ences in their expression pro¢les [6], G protein cou-
pling speci¢city [7] and patterns of desensitisation
[8^10] have been identi¢ed.
Of the many intracellular protein kinase (PK)s im-
plicated as mediators of mitogenesis, the extracellular
signal regulated kinases (ERKs) play an integral role
in the response of cells to various growth promoting
agents [11,12]. Both the TXA2 mimetics I-BOP and
U46619 activate ERK1 and ERK2 in porcine coro-
nary artery smooth muscle cells (SMCs), in rat aortic
and bovine SMCs, respectively [2,13^15]. Recently,
the stress activated protein kinases (SAPKs), c-Jun
N-terminal kinase (JNK) and p38, have been also
implicated in TXA2 mediated signal cascades
[16,17].
The F2-isoprostane, 8-epi prostaglandin F2K (8-
epiPGF2K) is produced in large quantities in vivo in
response to free radical induced mechanisms, and is a
potent renal, pulmonary and arterial vasoconstrictor
[18^20] with its actions being mediated, at least in
part, through interaction with vascular TPs [21,22].
Zhang et al. [23] demonstrated that 8-epiPGF2K is
less potent than U46619 in inducing contraction of
rat aorta. 8-EpiPGF2K has been reported to induce
ERK activity through the TP in porcine carotid ar-
teries [24]. It has also been suggested that 8-epi-
PGF2K may exert its biological actions in SMC
through activation of receptor sites related to but
distinct from TPs [25]. Thus, con£icting evidence ex-
ists regarding the actions of TXA2 and 8-epiPGF2K
in vascular SM. These discrepancies may be due to
di¡erences in the species investigated [2,13] or in tis-
sue and culture conditions employed [2,26]. Despite
these diverse studies, TXA2 and 8-epiPGF2K medi-
ated mitogenesis have not been investigated in detail
in human vascular SM.
Thus, in the present study, we sought to investi-
gate TP mediated mitogenesis in human vascular SM
in response to a TXA2 mimetic and in response to
the F2-isoprostane 8-epiPGF2K. Thus, the immortal-
ised human uterine ULTR cell line [27] was used as a
model vascular SMC line to investigate U46619 and
8-epiPGF2K mediated mitogenesis and activation of
mitogen activated protein kinase (MAPK) cascades
(ERK and JNK). Thereafter, as TXA2 signals in hu-
mans through two TP isoforms both of which were
demonstrated to be expressed in ULTR cells, human
embryonic kidney (HEK) 293 cell lines stably over-
expressing either TPK (HEK.TPK10 cells) or TPL
(HEK.TPL3 cells) were used to establish whether
both TPK and TPL individually contribute to
U46619 and 8-epiPGF2K mediated MAPK activation
in human tissues. Both TP isoforms mediated ERK
and JNK activation in response to U46619 and
8-epiPGF2K in the ULTR and the HEK 293 cell
lines. Whereas the selective TP antagonist SQ29548
abolished 8-epiPGF2K mediated ERK and JNK acti-
vation in HEK.TPK10 and HEK.TPL3 cells, it re-
sulted in only partial inhibition of 8-epiPGF2K medi-
ated MAPK activation in ULTR cells suggesting
that 8-epiPGF2K may signal through both TPK and
TPL and through other unidenti¢ed, SQ29548 insen-
sitive receptors in ULTR cells. This study provides
the ¢rst in depth analysis of the regulation of TP
mediated MAPK activation in human SMCs in re-
sponse to the TXA2 mimetic U46619 and the
F2-isoprostane 8-epiPGF2K. Additionally, this study
provides the ¢rst evidence that TPK and TPL indi-
vidually contribute to TP mediated MAPK activa-
tion in human tissue.
2. Materials and methods
2.1. Materials
U46619, 8-epiPGF2K and SQ29548 were purchased
from Cayman Chemical Company, Ann Arbor, MI,
USA. PD98059, GF109203X, tyrphostin AG1478
and H-89 were from Calbiochem-Novabiochem,
Nottingham, UK. Anti-ACTIVE MAPK and Anti-
ACTIVE JNK rabbit polyclonal antibodies and epi-
dermal growth factor (EGF) were purchased from
Promega Corporation, Madison, WI, USA. A⁄nity
puri¢ed rabbit polyclonal anti-JNK and anti-ERK
antibodies were from Santa Cruz Laboratories, San-
ta Cruz, CA, USA. Anisomycin, myelin basic protein
(MBP), platelet derived growth factor-LL (PDGF-
LL) and wortmannin were purchased from Sigma
Chemical Company, St. Louis, MO, USA.
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2.2. Culture of human uterine SMCs, HEK.TPK10
and HEK.TPL3 cells
The uterine SMC line ULTR, described by Perez-
Reyes et al. [27] was obtained from J.K. McDougall,
Department of Pathology, University of Washington,
Seattle, WA, USA. Cells were routinely grown in
Dulbecco’s minimal essential medium (DMEM),
10% foetal calf serum (FCS). Human embryonic kid-
ney (HEK) 293 cells were obtained from the Amer-
ican Type Culture Collection and were routinely
grown in minimal essential medium (MEM), 10%
FCS, unless otherwise indicated. The recombinant
HEK.TPK10 and HEK.TPL3 cell lines stably over-
expressing TPK and TPL, respectively, have been pre-
viously described [9,28].
2.3. Indirect immuno£uorescence of TPK and TPL
TP isoform speci¢c antibodies directed to peptide
sequences unique to TPK (amino acid residues
SLSLQPQLTQRSGLQ; K peptide) and TPL (amino
acid residues LPFEPPTGKALSRKD; L peptide) in-
tracellular C-tail sequences were raised in rabbits fol-
lowing conjugation to the carrier protein keyhole
limpet haemacyanin according to standard proce-
dures. Indirect immuno£uorescent detection of TPK
and TPL in permeabilised (2% paraformaldehyde) or,
as controls, in non-permeabilised cells, was per-
formed essentially as previously described [29]. As
additional negative controls, primary antibody was
omitted or the primary antibody was pre-incubated
with its cognate K or L peptide prior to exposure to
cells. Indirect immuno£uorescence detection of the
anti-rabbit £uorescein isothiocyanate (FITC) conju-
gated secondary antibody was observed using an
Olympus BX60 £uorescence microscope. In parallel,
nuclei were co-stained with 4,6-diamidino-2-phenyl-
indole (DAPI) as per the manufacturer’s instructions
(Sigma).
2.4. Determination of DNA and protein synthesis
ULTR cells were seeded at 2.5U105 cells/35 mm
dish in DMEM, 10% FCS. After 24 h, cells were
exposed to DMEM, 0.5% FCS to induce quiescence.
After a further 24 h, the medium was supplemented
with 1.5 WCi [3H]thymidine (60 Ci/mmol, Sigma) or
1.5 WCi [3H]leucine (60 Ci/mmol, American Radio-
chemicals) and cells were exposed to test agents
(U46619, 1 WM for 0^10 min; PDGF-LL, 20 ng/ml
for 10 min) at 37‡C. Protein and DNA synthesis was
determined essentially as previously described [30].
Results are presented as the mean data þ S.E.M.
(n = 3).
2.5. Determination of ERK activity using an in vitro
kinase assay
ULTR cells were seeded at 4U105 cells/60 mm
dish in DMEM, 10% FCS. After 24 h, cells were
exposed to DMEM, 0.5% FCS to induce quiescence.
After a further 48 h, the cells were exposed to test
agents (U46619, 1 WM for 0^10 min; PDGF-LL,
20 ng/ml for 10 min) at 37‡C. ERK activity was
determined by monitoring ERK mediated phosphor-
ylation of its substrate myelin basic protein as pre-
viously described [31] with the following modi¢ca-
tion. Endogenous ERK1/2 was recovered from the
cleared cellular lysates (150 Wg) by the addition of
a 1/2000 dilution of a non-inhibitory a⁄nity puri¢ed
anti-ERK-1/2 antibody (Santa Cruz).
2.6. Determination of ERK/JNK activation by
immunoblot analysis
ULTR cells were seeded at 1.5U106 cells/10 cm
dish in DMEM, 10% FCS. After 24 h, cells were
exposed to DMEM without any FCS to induce qui-
escence. HEK.TPK10 and HEK.TPL3 cells were
seeded at 1.5U106 cells/10 cm dish in MEM, 10%
FCS. After 24 h, cells were exposed to medium with-
out any FCS to induce quiescence. After a further
48 h, cells were exposed to test compounds at 37‡C,
as indicated in the respective ¢gure legends. Cellular
lysates were prepared as previously described [32].
Aliquots (30 Wg) of the cellular lysates were fraction-
ated by sodium dodecyl sulphate (SDS)^polyacryl-
amide gel electrophoresis on 12.5% gels followed by
electroblotting onto PVDF membrane. Thereafter,
membranes were screened by immunoblot analysis
using a rabbit anti-ACTIVE ERK antibody (Prom-
ega) or a rabbit anti-ACTIVE JNK antibody (Prom-
ega) as appropriate, to detect dual phosphorylated
ERK (ppERK1/2) and dual phosphorylated JNK
(ppJNK1/2), respectively, as recommended by the
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supplier. Subsequently, membranes were re-screened
with either a⁄nity puri¢ed rabbit anti-ERK anti-
body (Santa Cruz) or anti-JNK antibody (Santa
Cruz) to detect total ERK protein and total JNK
protein, respectively. Immunocomplexes were visual-
ised using the chemiluminescence detection system,
as described by the supplier (Roche); in each case,
immunoblots are presented as a representative blot
from at least three independent experiments. Alter-
natively, signals from ppERK1 and ppERK2 or
Fig. 1. U46619 mediated ERK activation in ULTR cells. (A) ULTR cells were stimulated with U46619 for 0^10 min (0^10P) and
U46619 mediated ERK activation was determined using an in vitro kinase assay as described in Section 2. As a positive control
(+ve), cells were incubated with PDGF-LL. Positions of the [Q32P]-labelled myelin basic protein (MBP) are indicated by the arrow.
(B) Concentration dependent e¡ect of U46619 (0^1000 nM, 10 min) and (C) time dependent e¡ect of U46619 (100 nM, 0^60 min) on
ERK1 and ERK2 activation in ULTR cells. Upper panels of (B) and (C) Blots were screened with anti-ACTIVE ERK to detect the
phosphorylated, active forms of ERK (ppERK1/2) whereas in the lower panels of (B) and (C) blots were screened with anti-ERK
antibodies to detect ERK1/2 immunoreactive protein. Results are representatives of at least three independent experiments. Panels (D)
and (E) Fold increases in ERK phosphorylation (ppERK1/2) in panels (B) and (C), respectively, are presented as mean fold increases
of basal ERK phosphorylation þ S.E.M. (n = 3), where the levels of basal ERK phosphorylation in vehicle treated cells are assigned a
value of 1.0. *P9 0.05 and **P9 0.01 indicate that the levels of U46619 mediated ERK activation (ppERK) were signi¢cantly greater
relative to basal levels.
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ppJNK1 and ppJNK2 were quanti¢ed by scanning
densitometry using a UVP gel documentation system
and the combined ppERK1/2 or ppJNK1/2 signals
are presented as mean fold increase of basal ERK
phosphorylation þ standard error of the mean
(S.E.M.), where the levels of basal ERK phosphory-
lation in vehicle treated cells are assigned a value of
1.0. Statistical analyses were carried out using the
unpaired Student’s t-test using the Statworks Analy-
sis Package. P-values90.05 were considered to indi-
cate a statistically signi¢cant di¡erence.
3. Results
3.1. E¡ect of U46619 on ERK activation in
ULTR cells
To elucidate the mitogenic/hypertrophic capabil-
ities of TXA2 in human uterine SMCs, U46619
mediated changes in DNA and protein synthesis
and activation of the ERK signalling cascade were
investigated in ULTR cells. U46619 and PDGF
resulted in a 1.23 þ 0.07-fold (P9 0.001) and
1.21 þ 0.03-fold (P9 0.001) increase in [3H]thymidine
incorporation, respectively. Whereas PDGF resulted
in a 1.51 þ 0.17-fold (P9 0.001) increase in
[3H]leucine incorporation, U46619 resulted in a
1.89 þ 0.11-fold (P9 0.001) increase in [3H]leucine in-
corporation. Thereafter, an in vitro kinase assay was
used to evaluate the ability of activated ERK to
phosphorylate its substrate myelin basic protein
(MBP; [33]) in response to U46619 stimulation.
Whereas detectable levels of non-speci¢c MBP phos-
phorylation were observed for non-treated cells (Fig.
1A; time zero) or vehicle only treated cells (data not
shown), exposure of quiescent ULTR cells to
U46619 for 2^10 min resulted in a time dependent
increase in phosphorylation of MBP, with maximal
phosphorylation observed after 5 min (Fig. 1A,
P9 0.05). Exposure of the quiescent ULTR cells to
PDGF-LL also induced MBP phosphorylation.
As an alternative method to evaluate U46619 in-
duced ERK1 and ERK2 activation, anti-ACTIVE
ERK antibodies that preferentially recognise their
dually phosphorylated, active forms (phosphorylated
ppERK1/2) were utilised. Furthermore, an a⁄nity
puri¢ed anti-ERK antibody was routinely used to
detect total ERK1 and ERK2 (ERK) protein present
in the cellular lysate, thus ensuring equal expression
and protein loading of ERK1 and ERK2. U46619
mediated a dose dependent phosphorylation of
ERK1 (ppERK1) and ERK2 (ppERK2) in ULTR
cells with maximal activation observed at 100^300
nM U46619 (Fig. 1B,D). U46619 also mediated a
time dependent activation of ERK1 and ERK2
with maximal activation observed at 5^10 min (Fig.
1C,E). It was noteworthy that in contrast to that
observed with the previous in vitro kinase assays,
routinely only low levels of non-speci¢c ERK activa-
tion were observed in vehicle only treated cells using
Fig. 2. Modulation of U46619 mediated ERK activation.
ULTR cells were pre-incubated with either SQ29548 (1 WM,
1 min; lane 3), PD98059 (10 WM, 30 min; lane 4), H-89
(10 WM, 5 min; lane 5), PTX (50 ng/ml, 16 h; lane 6),
GF109203X (500 nM, 30 min; lane 7) or wortmannin (400 nM,
30 min; lane 8). Subsequently, U46619 (100 nM) was added for
10 min (lanes 3^8), with cells exposed exclusively to U46619
(100 nM for 10 min; lane 2) or with vehicle alone (lane 1) serv-
ing as references. (A) Immunoblots were screened with anti-AC-
TIVE ERK to detect the phosphorylated, active forms of ERK
(ppERK1/2) whereas in (B) blots were screened with anti-ERK
antibodies to detect ERK1/2 immunoreactive protein. Results
are representatives of at least three independent experiments.
(C) Fold increases in ERK phosphorylation (ppERK1/2) in (A)
are presented as mean fold increases of basal ERK phosphory-
lation þ S.E.M. (n = 3^5), where the levels of basal ERK phos-
phorylation in vehicle treated cells are assigned a value of 1.0.
*P9 0.05 and **P9 0.01 indicate that the levels of U46619
mediated ppERK activation (lane 2) were signi¢cantly reduced
in the presence of the respective pharmacological inhibitors
(lanes 3^8).
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the anti-ACTIVE ERK antibody. Furthermore, as
MBP may be a substrate for phosphorylation by
protein kinases other than ERK, coupled to the
fact that the in vitro kinase procedure does not dif-
ferentiate between ERK1 and ERK2 activation,
makes the former protocol a less speci¢c and infor-
mative method for measurement of ERK activation.
For these reasons, the latter approach using anti-
ACTIVE ERK antibodies was used in preference to
the in vitro kinase assay for further characterisation
of the ERK pathways in human SMCs.
Pre-treatment of ULTR cells with SQ29548 (Fig.
2) or with PD98059 (Fig. 2) reduced U46619 induced
ERK1/2 activation to levels that were not signi¢-
cantly di¡erent from those observed in non-stimu-
lated ULTR cells. Whereas pre-treatment of ULTR
cells with the PKA inhibitor H-89 resulted in a near
complete inhibition of U46619 mediated activation
of ERK1/2 (Fig. 2), pertussis toxin (PTX) did not
a¡ect U46619 mediated activation of ERK1/2 (Fig.
2). The PKC inhibitor GF109203X (Fig. 2) or the
phosphoinositide 3-kinase (PI3K) inhibitor wortman-
nin (Fig. 2) each resulted in a partial, though signi¢-
cant, inhibition of ERK1/2 activation when com-
pared to ULTR cells exposed exclusively to
U46619. H-89, GF109203X and wortmannin com-
bined did not fully abolish U46619 mediated ERK
activation (data not shown). These data con¢rm that
U46619 induced activation of ERK1/2 in ULTR cells
is mediated through the TP(s) in a MEK1/2 depen-
dent manner and suggest that PKA, PKC and PI3K
play a role in these events.
3.2. E¡ect of tyrphostin AG1478 on U46619 mediated
ERK activation in ULTR cells
Many G protein coupled receptors (GPCRs) in-
duce the activation of mitogenic signalling by stim-
ulating tyrosine kinase signalling cascades [34^37].
For example, GPCRs stimulate tyrosine phosphory-
lation by inducing the transactivation of a receptor
tyrosine kinase (RTK) such as the EGF receptor,
platelet derived growth factor receptor and insulin
like growth factor-1 [34,35]. The ability of tyrphostin
AG1478, a selective EGF receptor inhibitor, to block
U46619 mediated ERK activation in ULTR cells was
examined. Exposure of ULTR cells to U46619 (100
nM) and EGF (10 ng/ml) for 10 min resulted in the
activation of ERK1 and ERK2 (Fig. 3A,C). More-
over, pre-treatment of ULTR cells with AG1478 sig-
ni¢cantly inhibited both EGF and U46619 mediated
ERK1 and ERK2 activation (Fig. 3A,C). These ¢nd-
ings suggest that U46619 mediated activation of the
ERK signalling cascade also involves transactivation
of the EGF receptor.
3.3. E¡ect of 8-epiPGF2K on ERK activation in
ULTR cells
Exposure of ULTR cells to 8-epiPGF2K resulted in
a dose dependent activation of ERK1 and ERK2
with maximal activation observed when cells were
exposed to 300 nM 8-epiPGF2K (Fig. 4A,C). Addi-
Fig. 3. E¡ect of tyrphostin AG1478 on U46619 mediated ERK
activation. ULTR cells were pre-incubated with tyrphostin
AG1478 (125 nM, 30 min; lanes 3 and 5). Subsequently,
U46619 (100 nM; lane 3) or EGF (10 ng/ml; lane 5) was added
for 10 min, with cells exposed to U46619 alone (100 nM for
10 min; lane 2), EGF alone (10 ng/ml for 10 min; lane 4) or
with vehicle alone (lane 1) serving as references. (A) Immuno-
blots were screened with anti-ACTIVE ERK to detect the phos-
phorylated, active forms of ERK (ppERK1/2) whereas in (B)
blots were screened with anti-ERK antibodies to detect ERK1/2
immunoreactive protein. Results are representatives of four in-
dependent experiments. (C) Fold increases in ERK phosphory-
lation (ppERK1/2) in (A) are presented as mean fold increases
of basal ERK phosphorylation þ S.E.M. (n = 4), where the levels
of basal ERK phosphorylation in vehicle treated cells are as-
signed a value of 1.0. *P9 0.05 and **P9 0.01 indicate that
the levels of U46619 or EGF mediated ppERK activation
(lanes 2 and 4, respectively) were signi¢cantly reduced in the
presence of AG1478 (lanes 3 and 5, respectively).
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tionally, 8-epiPGF2K induced a time dependent acti-
vation of ERK1 and ERK2 with maximal phosphor-
ylation occurring after 10 min reaching near basal
levels after 60 min (Fig. 4B,D).
Whereas pre-treatment of ULTR cells with
PD98059 inhibited 8-epiPGF2K induced ERK1/2 ac-
tivation (Fig. 4B, P9 0.05), SQ29548 reduced, but
did not lead to a statistically signi¢cant inhibition
of, ERK1 and ERK2 activation (Fig. 5A,C,
Pv 0.05) in response to 8-epiPGF2K. These ¢ndings
suggest that 8-epiPGF2K induced activation of
ERK1/2 in ULTR cells is mediated only partially
through TP(s) and that 8-epiPGF2K is less potent
than U46619 in mediating ERK1/2 activation.
Fig. 4. 8-EpiPGF2K mediated ERK activation in ULTR cells. (A) Dose dependent (0^1000 nM, 10 min) and (B) time dependent (300
nM, 0^60 min) activation of ERK1/2 in response to 8-epiPGF2K. Alternatively, in (B) (8-epiPGF2K and PD98059), cells were pre-incu-
bated with PD98059 (10 WM, 30 min) prior to stimulation of cells with 8-epiPGF2K (300 nM, 10 min). Upper panels, blots were
screened with anti-ACTIVE ERK to detect the phosphorylated, active forms of ERK (ppERK1/2) whereas in the lower panels, blots
were screened with anti-ERK antibodies to detect ERK1/2 immunoreactive protein. Results are representatives of at least three inde-
pendent experiments. (C) and (D) Fold increases in ERK phosphorylation (ppERK1/2) in (A) and (B), respectively, are presented as
mean fold increases of basal ERK phosphorylation þ S.E.M. (n = 3^7), where the levels of basal ERK phosphorylation in vehicle
treated cells are assigned a value of 1.0. *P9 0.05 and **P9 0.01 indicate that the levels of 8-epiPGF2K mediated ERK activation
(ppERK) were signi¢cantly greater relative to basal levels.
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Pre-treatment of ULTR cells with wortmannin,
H-89 or GF109203X each signi¢cantly inhibited
8-epiPGF2K mediated activation of ERK1/2 com-
pared to cells exposed to 8-epiPGF2K alone (Fig.
5A,C). PTX did not a¡ect 8-epiPGF2K mediated ac-
tivation of ERK1/2 (Fig. 5A,C). These ¢ndings sug-
gest that PI3K, PKA and PKC play a role in 8-epi-
PGF2K induced ERK activation. Moreover, pre-
treatment of ULTR cells with AG1478 signi¢cantly
inhibited 8-epiPGF2K mediated ERK1 and ERK2
activation suggesting 8-epiPGF2K induced transacti-
vation of the EGF receptor (data not shown).
3.4. E¡ect of U46619 and 8-epiPGF2K on JNK1 and
JNK2 activation in ULTR cells
To investigate the role of TP on the SAPK cas-
cades, quiescent ULTR cells were exposed to U46619
Fig. 5. Modulation of 8-epiPGF2K mediated ERK activation.
ULTR cells were pre-incubated with either SQ29548 (1 WM,
1 min; lane 3), wortmannin (400 nM, 30 min; lane 4), H-89
(10 WM, 5 min; lane 5), PTX (50 ng/ml, 16 h; lane 6) or
GF109203X (500 nM, 30 min; lane 7). Subsequently, 8-epi-
PGF2K (300 nM) was added for 10 min (lanes 3^7), with cells
exposed to 8-epiPGF2K alone (300 nM for 10 min; lane 2) or
with vehicle alone (lane 1) serving as references. (A) Immuno-
blots were screened with anti-ACTIVE ERK to detect the phos-
phorylated, active forms of ERK (ppERK1/2). (B) Immuno-
blots were screened with anti-ERK antibodies to detect ERK1/2
immunoreactive protein. (C) Fold increases in ERK phosphory-
lation (ppERK1/2) in (A) are presented as mean fold increases
of basal ERK phosphorylation þ S.E.M. (n = 3^4), where the
levels of basal ERK phosphorylation in vehicle treated cells are
assigned a value of 1.0. *P9 0.05 and **P9 0.01 indicate that
the levels of 8-epiPGF2K mediated ppERK activation (lane 2)
were signi¢cantly reduced in the presence of the respective
pharmacological inhibitors (lanes 3^7).
Fig. 6. E¡ect of U46619 and 8-epiPGF2K on JNK activation in
ULTR cells. ULTR cells were stimulated with either U46619
(100 nM; (A) lanes 2^4) or 8-epiPGF2K (300 nM; (B) lanes 2^
4) for 10, 20 and 60 min, respectively, or with vehicle alone
(control; (A) and (B), lane 1) or were pre-incubated with
SQ29548 (1 WM, 1 min) prior to stimulation with 100 nM
U46619 (A, lane 5) or 300 nM 8-epiPGF2K (B, lane 5) for
10 min. As positive control, cells were incubated with anisomy-
cin (10 Wg/ml) for 60 min (A and B, lane 6). Upper panels,
blots were screened with anti-ACTIVE JNK to detect the phos-
phorylation, active forms of JNK (ppJNK1/2) whereas in the
lower panels, blots were screened with anti-JNK antibodies to
detect JNK1/2 immunoreactive protein. Results are representa-
tives of three independent experiments. (C) Fold increases in
U46619 and 8-epiPGF2K mediated ppJNK1/2 in (A) and (B),
respectively, are presented as mean fold increases of basal JNK
phosphorylation þ S.E.M. (n = 3), where the levels of basal JNK
phosphorylation in vehicle treated cells are assigned a value of
1.0. *P9 0.05 and **P9 0.01 indicate that the levels of U46619
or 8-epiPGF2K mediated JNK activation (ppJNK) were signi¢-
cantly greater relative to basal levels.
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or to 8-epiPGF2K for 10^60 min, or as a positive
control, to the protein synthesis inhibitor anisomycin
for 60 min. Whereas anisomycin induced activation
of both JNK1 and JNK2 (Fig. 6A,B), both U46619
and 8-epiPGF2K each induced a weak, time depen-
dent activation of JNK1 and JNK2 (Fig. 6A^C).
Immunoblot analysis using an a⁄nity puri¢ed anti-
JNK antibody revealed that both JNK1 and JNK2
are abundantly expressed in ULTR cells (Fig. 6A).
The TP antagonist SQ29548 blocked U46619 medi-
ated JNK activation (Fig. 6A; P9 0.05) but resulted
in only a marginal, statistically insigni¢cant, inhibi-
tion of 8-epiPGF2K mediated JNK activation (Fig.
6B; Pv 0.05).
3.5. Immunodetection of TPK and TPL in a
human uterine SMC line
Indirect immuno£uorescent staining of ULTR
cells with the TPK and TPL speci¢c antisera con-
¢rmed expression of both TPK and TPL in mem-
branes of permeabilised (Fig. 7A,B) but not in non-
permeabilised ULTR cells (data not shown). The
speci¢city of the TP isoform selective antibodies
was further con¢rmed in peptide competition studies
whereby the cognate K peptide blocked immunode-
tection by anti-TPK antisera (Fig. 7C) but not by
anti-TPL antisera (data not shown) and vice versa
(Fig. 7D and data not shown). These data corrobo-
rate RT-PCR analyses [6] and con¢rm that both TPK
and TPL mRNA and protein are expressed in the
human ULTR cell line under study.
3.6. E¡ect of U46619 and 8-epiPGF2K on MAPK
activation in HEK.TPK10 and HEK.TPL3 cells
To establish whether U46619 induced activation of
ERK1 and ERK2 was mediated through one or both
TP isoforms, non-transfected HEK 293 cells,
HEK.TPK10 and HEK.TPL3 cells were exposed to
U46619, with vehicle treated cells serving as a con-
trol. Exposure of HEK 293 cells to U46619 resulted
in a marginal, statistically insigni¢cant activation of
ERK1 and ERK2 when compared to cells treated
with vehicle only (Fig. 8A,B), probably due to low
levels of endogenous TP(s) present in this cell type
Fig. 7. Expression of TPK and TPL in ULTR cells. Indirect immuno£uorescent staining of TPK and TPL in permeabilised ULTR cells
was performed as described in Section 2. Within each panel, the upper photograph represents the FITC immuno£uorescence and the
lower photograph illustrates the localisation of nuclei following DAPI staining. (A) Anti-TPK antiserum; (B) anti-TPL antiserum;
(C) anti-TPK antiserum pre-incubated with a TPK speci¢c peptide; (D) anti-TPL antiserum pre-incubated with a TPL speci¢c peptide.
Results presented are representatives of at least three independent experiments.
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[38]. Exposure of HEK.TPK10 and HEK.TPL3 cells
to U46619 induced a TP isoform speci¢c activation
of ERK1 and ERK2 when compared to vehicle
treated cells (Fig. 8A,B). U46619 mediated ERK ac-
tivation in HEK.TPK10 and HEK.TPL3 cells was
completely blocked by SQ29548 and by PD98059
(data not shown). Additionally, exposure of
HEK.TPK10 and HEK.TPL3 cells to U46619 in-
Fig. 8. E¡ect of U49919 on ERK1/2 and JNK1/2 activation in
HEK.TPK10 and HEK.TPL3 cells. (A) and (C) E¡ect of
U46619 (100 nM, 10 min) on ERK and JNK activation, respec-
tively, in HEK 293 (ERK only), HEK.TPK10 and HEK.TPL3
cells. Upper panels of (A) and (C): Blots were screened with
anti-ACTIVE ERK (A) or anti-ACTIVE JNK (C) to detect the
phosphorylated, active forms of ERK (ppERK1/2), and JNK
(ppJNK1/2), respectively. In the lower panels of (A) and (C),
blots were screened with anti-ERK and anti-JNK antibodies to
detect ERK1/2 and JNK1/2 immunoreactive protein, respec-
tively. Results are representatives of three independent experi-
ments. (B) and (D) Fold increases in ERK (ppERK1/2) or
JNK (ppJNK) phosphorylation in (A) and (C), respectively, are
presented as mean fold increases of basal phosphorylation þ
S.E.M. (n = 3), where the levels of basal phosphorylation in ve-
hicle treated cells are assigned a value of 1.0. *P9 0.05 and
**P9 0.01 indicate that the levels of U46619 mediated ERK/
JNK activation (ppERK or ppJNK) were signi¢cantly greater
relative to basal levels.
Fig. 9. 8-EpiPGF2K mediated ERK activation in HEK.TPK10
and HEK.TPL3 cells. Time dependent e¡ect of 8-epiPGF2K (300
nM; 0, 5, 10, 20 and 60 min) on ERK1 and ERK2 activation
in HEK.TPK10 cells (A, lanes 1^5) and in HEK.TPL3 cells
(B, lanes 1^5). Additionally, in (A) (HEK.TPK10 cells) and
(B) (HEK.TPL3 cells), cells were pre-incubated with SQ29548
(1 WM, 1 min; lane 6) or PD98059 (10 WM, 30 min; lane 7) pri-
or to stimulation of cells with 8-epiPGF2K (300 nM, 10 min).
Upper panels of (A) and (B): Blots were screened with anti-
ACTIVE ERK to detect the phosphorylated, active forms of
ERK (ppERK1/2) whereas in the lower panels of (A) and (B),
blots were screened with anti-ERK antibodies to detect ERK1/2
immunoreactive protein. Results are representatives of three in-
dependent experiments. (C) Fold increases in ERK (ppERK1/2)
phosphorylation in (A) (HEK.TPK10 cells) and (B) (HEK.TPL3
cells), respectively, are presented as mean fold increases of basal
ERK phosphorylation þ S.E.M. (n = 3), where the levels of basal
ERK phosphorylation in vehicle treated cells are assigned a val-
ue of 1.0. *P9 0.05 and **P9 0.01 indicate that the levels of
8-epiPGF2K mediated ERK activation (ppERK) were signi¢-
cantly greater relative to basal levels.
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duced a TP isoform speci¢c activation of JNK1 and
JNK2 when compared to the vehicle treated control
cells (Fig. 8C,D). However, the level of TP mediated
JNK activation was considerably lower than the level
of ERK activation despite the presence of high levels
and JNK1/2 in these cells (Fig. 8C). These ¢ndings
suggest that both TPK and TPL independently direct
U46619 mediated ERK1/2 and JNK1/2 activation.
To establish whether the F2-isoprostane, 8-epi-
PGF2K elicits ERK1 and ERK2 activation through
both TPK and TPL, HEK.TPK10 and HEK.TPL3
cells were exposed to 8-epiPGF2K for 0^60 min.
Exposure of HEK.TPK10 and HEK.TPL3 cells to
8-epiPGF2K elicited a similar time dependent activa-
tion of ERK1 and ERK2, with maximal activation
detected after 10^20 min exposure (Fig. 9A^C). Fur-
thermore, pre-treatment with either SQ29548 or
PD98059 completely abolished ERK1/2 activation
when compared to cells exposed exclusively to 8-epi-
PGF2K (Fig. 9A,B). Exposure of HEK.TPK10 and
HEK.TPL3 cells to 8-epiPGF2K led to time depen-
dent JNK1 and JNK2 activation with maximal acti-
vation detected following 20 min incubation (Fig.
10A^C). Pre-treatment of cells with SQ29548 re-
sulted in a near complete inhibition of 8-epiPGF2K
mediated JNK activation in both HEK.TPK10
(P9 0.001) and HEK.TPL3 (P9 0.001) cells (Fig.
10A,B).
4. Discussion
Activation of the ERK signalling cascade is an
obligatory step for growth factor induced protein
synthesis in aortic SMC [39]. Previous studies have
demonstrated TP induced ERK activation in rat, bo-
vine and porcine VSM [2,13,14]. However, TP medi-
ated ERK activation has not been demonstrated in
human SMC. Thus, in the present study, to ascertain
the role of TXA2 in VSM hypertrophy/mitogenesis,
the ability of the TXA2 mimetic U46619 and the F2-
isoprostane, 8-epiPGF2K to activate the MAPK sig-
nalling cascades was investigated using the previously
described human uterine ULTR cells [27] as a model
cell line for cultured human VSM cells. In addition,
as TXA2 signals through two related TPK and TPL
receptor isoforms in humans, but not in other species
thus far investigated, it was unknown whether both
TP isoforms contribute to TP mediated mitogenic
signalling in human tissue. Expression of both TPK
and TPL in the ULTR SMC line [27] under study
was con¢rmed by indirect immuno£uorescence using
TP isoform speci¢c antibodies corroborating pre-
vious RT-PCR analyses [6].
Fig. 10. 8-EpiPGF2K mediated JNK activation in HEK.TPK10
and HEK.TPL3 cells. Time dependent e¡ect of 8-epiPGF2K
(300 nM; 0, 5, 10, 20 and 60 min) on JNK1 and JNK2 activa-
tion in HEK.TPK10 cells (A, lanes 1^5) and in HEK.TPL3 cells
(B, lanes 1^5). Additionally, HEK.TPK10 cells (A, lane 6) and
HEK.TPL3 cells (B, lane 6) were pre-incubated with SQ29548
(1 WM, 1 min) prior to stimulation with 8-epiPGF2K (300 nM,
10 min). Upper panels of (A) and (B): Blots were screened with
anti-ACTIVE JNK to detect the phosphorylated, active forms
of JNK (ppJNK1/2) whereas in the lower panels of (A) and
(B), blots were screened with anti-JNK antibodies to detect
JNK1/2 immunoreactive protein. Results are representatives of
three independent experiments. (C) Fold increases in JNK
(ppJNK1/2) phosphorylation in (A) (HEK.TPK10 cells) and
(B) (HEK.TPL3 cells), respectively, are presented as mean fold
increases of basal JNK phosphorylation þ S.E.M. (n = 3), where
the levels of basal JNK phosphorylation in vehicle treated cells
are assigned a value of 1.0. *P9 0.05 and **P9 0.01 indicate
that the levels of 8-epiPGF2K mediated JNK activation
(ppJNK) were signi¢cantly greater relative to basal levels.
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Thus, we initially examined the e¡ect of U46619
on activation of ERK signalling in ULTR cells.
U46619 elicited both a weak hypertrophic and hyper-
plastic e¡ect and also mediated a time and concen-
tration dependent activation of ERK1/2 in ULTR
cells which was inhibited by MEK1/2 inhibitor
PD98059 and by the selective TP antagonist
SQ29548. Thereafter, we sought to de¢ne the factors
that regulate TP mediated ERK activation. The sec-
ond messenger kinases, such as PKA, PKC and
PI3K, play a central role in modulating the ERK
signalling cascade in response to a variety of extra-
cellular stimuli [11,12,40]. TP receptors functionally
couple to Gq family members, to mediate activation
of phospholipase (PL) C and more recently it has
been demonstrated that the TPs may also couple to
G12 members, though the e¡ectors remain to be fully
de¢ned [38,41^43]. In the current study, we demon-
strate that TXA2 exerts its e¡ects, in part, through
PKC, suggesting a role for Gq members and raf-1 in
TXA2 mediated ERK activation in human SMC
[11,12]. These data in human ULTR cells are in
agreement with previous studies that established
that the PKC inhibitor staurosporine inhibited
[3H]thymidine uptake by porcine coronary artery
SMCs in response to the TXA2 mimetic I-BOP [2].
A number of studies have shown that increases in
cAMP and resulting activation of PKA decreases
ERK activation [44], possibly by inhibiting raf-1 ac-
tivation or by inhibiting certain PKC isoforms [40].
However, cAMP may also elicit a positive e¡ect on
ERK activation [45]. Here, we demonstrate that in-
hibition of PKA with H-89 in ULTR cells inhibited
U46619 mediated ERK1/2 activation suggesting that
activation of ERK through TP is partially PKA de-
pendent. These data suggest that PKA functions as a
positive regulatory element for TXA2 induced ERK
activation in human SMC by mechanisms currently
unknown but which may include inhibition of PKA
sensitive phosphatases or by PKA mediated activa-
tion of a MEK kinase distinct from raf-1 [40] such as
A-raf or B-raf [46].
Among the functional di¡erences ascribed to the
human TP isoform, TPK and TPL oppositely regu-
late adenylyl cyclase with TPK activating it, through
GKs and TPL inhibiting it, through GKi [7]. Here we
show that PTX did not alter U46619 induced activa-
tion in ULTR cells possibly suggesting that the PTX
sensitive GKi coupled TPL may not activate the ERK
signalling cascade in this cell type. Alternatively,
stimulation of TPL may lead to GKi derived LQ sub-
units which mediate ERK activation; however, the
inhibitory e¡ects of PTX may be masked by a strong
TPK mediated ERK activation through GKs/GKq
coupling. Our data demonstrating that PTX did
not a¡ect TP mediated ERK signalling in human
ULTR cells are in agreement with previous studies
by Sachinidis et al. [47] who reported that PTX did
not a¡ect TXA2 mediated mitogenic signalling in rat
aortic SMCs. However, in contrast to these ¢ndings
[47] and studies therein, it was recently reported that
TXA2 mediated MAPK signalling in endothelial
ECV304 cells was inhibited by PTX implicating a
role for Gi/Go members in TP mediated MAPK sig-
nalling [48]. The molecular bases of these reported
di¡erences are currently unknown but may possibly
be accounted for by widely reported tissue/cell de-
pendent di¡erences in MAPK signal transduction
cascades in response to a given ligand.
PI3K has been implicated as having a central role
in cell proliferation [11,12,49]. Speci¢cally, recent
studies in rat A7r5 SMC cultures transiently trans-
fected with the human TPK isoform demonstrated
that the TXA2 mimetic I-BOP led to increased tyro-
sine phosphorylation of the 85 kDa adapter subunit
of PI3K but also of the TPK receptor itself [50]. In
this study, we show that PI3K plays a role in TXA2
mediated ERK activation in uterine SMC, since pri-
or exposure of ULTR cells to wortmannin partially
inhibited U46619 induced ERK1/2 activation. Fur-
ther studies are required to underpin the precise
mechanism of U46619 mediated PI3K signalling
and ERK activation.
Transactivation of receptor tyrosine kinases
(RTKs) such as the EGF receptor, the PDGF recep-
tor or the insulin like growth factor receptor, follow-
ing GPCR stimulation has been implicated in GPCR
mediated activation of ERK [34,37]. Speci¢cally,
transactivation of RTKs has been demonstrated for
many GPCRs including the lysophosphatidic acid
(LPA), K2A and L2 adrenergic and thrombin recep-
tors [34,36,37]. In this study, we have shown that TP
mediated activation of ERK in response to U46619
in ULTR cells is dependent on transactivation of the
EGF receptor as AG1478, a speci¢c inhibitor of the
EGF receptor, inhibited both EGF and U46619
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mediated ERK activation. Consistent with our data,
Gao et al. [48] recently established that the TXA2
mimetic I-BOP led to transactivation of the EGF
receptor in ECV304 cells in a PTX dependent mech-
anism. The precise mechanism of TP mediated EGF
receptor transactivation and whether TP signals
through transactivation of other RTKs in ULTR
cells remain to be fully explored.
The F2-isoprostane 8-epiPGF2K has potent biolog-
ical activity, including reversible platelet aggregation
and vascular SMC contraction, the e¡ects of which
were found to be inhibited, either wholly or in part,
by the TXA2 antagonist, SQ29548 [51,24,38]. Here,
we show that 8-epiPGF2K mediates a time and con-
centration dependent activation of ERK1 and ERK2
in ULTR cells. Furthermore, consistent with its par-
tial agonist e¡ect on TPs [51], 8-epiPGF2K is slower
and is less potent than U46619 in eliciting ERK ac-
tivation in ULTR cells. Whereas the TXA2 antago-
nist SQ29548 abolished U46619 induced activation
of ERK, it only partially inhibited 8-epiPGF2K medi-
ated ERK activation. These ¢ndings suggest that
8-epiPGF2K exerts its e¡ects, at least in part, through
SQ29548 sensitive TPs but also suggest that 8-epi-
PGF2K may activate alternative receptor(s) other
than SQ29548 sensitive TPs in human uterine
SMCs. Correlating with U46619 induced activation
of ERK1 and ERK2, 8-epiPGF2K induced activation
of ERK1 and ERK2 is partially activated by PI3K
and exhibited a partial dependence on PKA and
PKC. Whereas PTX had no e¡ect, the EGF receptor
inhibitor AG1478 inhibited 8-epiPGF2K mediated
ERK activation in ULTR cells (data not shown) in-
dicating that 8-epiPGF2K also mediated transactiva-
tion of the EGF receptor in ULTR cells.
Recently, Karim et al. [17] reported that in porcine
SMC, whereas U46619 weakly activated ERK1/2,
the SAPK, JNK1 was strongly activated. To inves-
tigate if TP(s) expressed in the human VSM (ULTR)
cells mediated JNK1 and JNK2 activation, U46619
and 8-epiPGF2K mediated JNK activation was inves-
tigated. Whereas anisomycin elicited strong activa-
tion of JNK1 and JNK2, both U46619 and 8-epi-
PGF2K elicited only weak activation of JNK1/2 in
ULTR cells. This suggests that in human SMC, TP
agonists act primarily as mitogenic/hypertrophic
agents and may possibly explain the poor activation
of the JNK cascade when compared to the ERK
cascade in response to U46619 and 8-epiPGF2K in
ULTR cells. However, this does not rule out the
possibility that TXA2 and/or 8-epiPGF2K may act
as a stress factor in certain pathophysiological states.
As previously stated, TXA2 signals through two
TP receptor isoforms, termed TPK and TPL. Consis-
tent with previous ¢ndings that the mRNAs for both
TPK and TPL are expressed in ULTR cells [6], iso-
form speci¢c antibodies permitted the immunochem-
ical detection of both TP receptors thereby con¢rm-
ing their expression at the protein level in ULTR
cells. Thus, to establish whether both TP isoforms
activate the MAPK signalling cascades, the previ-
ously described HEK 293 cell lines which stably
over-express either TPK (HEK.TPK10 cells) or TPL
(HEK.TPL3 cells) were utilised [9,28]. Exposure of
non-transfected HEK 293 cells to U46619 elicited
weak activation of ERK and JNK (data not shown).
However, for the stable HEK.TPK10 and HEK.TPL3
cell lines, both TP isoforms were demonstrated to
activate the ERK and JNK signalling cascades in
response to U46619. These data provide the ¢rst evi-
dence that both TPK and TPL independently mediate
ERK and JNK activation in human tissues.
Thereafter, the ability of TPK and TPL to inde-
pendently mediate 8-epiPGF2K induced activation
of ERK and JNK was investigated. It was found
that 8-epiPGF2K induced a similar time dependent
activation of ERK and JNK through both TPK
and TPL isoforms. As previously stated, in ULTR
cells a similar time pro¢le of ERK activation was
observed, with 10 min required for maximal ERK
activation in response to 8-epiPGF2K. Interestingly,
whereas SQ29548 led to only partial antagonism of
8-epiPGF2K induced activation of ERK and JNK in
ULTRs, complete inhibition of ERK and JNK acti-
vation was observed when HEK.TPK10 and
HEK.TPL3 cells were pre-treated with SQ29548.
Thus, it appears that 8-epiPGF2K exerts its e¡ects
exclusively through SQ29548 targeted TPs in
HEK.TPK10 and HEK.TPL3 cells and, thus, may
re£ect tissue speci¢c variations in the expression of
the hypothesised vascular smooth muscle speci¢c
8-epiPGF2K receptor [25]. This may account for the
di¡erent levels of SQ29548 antagonism observed for
8-epiPGF2K induced ERK and JNK activation in
HEK.TPK10 cells, HEK.TPL3 cells compared with
human ULTR cells.
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In conclusion, U46619 and 8-epiPGF2K elicit
strong activation of the ERK cascade in human
SMC. TP mediated ERK activation in human ute-
rine SMCs may also involve transactivation of the
EGF receptor. The signalling intermediate PI3K ap-
pears to play an integral role in TXA2 induced acti-
vation of the ERK cascade though the precise mech-
anism of PI3K signalling in response to TP
activation remains to be de¢ned. Both PKA and
PKC function as positive regulatory elements in
TXA2 induced activation of ERK. U46619 and
8-epiPGF2K led to weak activation of the SAPK/
JNK cascade when compared with their activation
of the ERK cascade. This may re£ect the inherent
nature of the TXA2 induced signalling cascades in
human SMCs, in that the ERK pathway primarily
controls cellular proliferation (for example, in re-
sponse to vascular injury), whereas the SAPK path-
way is generally activated in response to environmen-
tal stress. In addition, both TPK and TPL
independently mediate ERK and JNK activation in
response to U46619 and in response to 8-epiPGF2K.
However, in view of the di¡erential antagonistic ef-
fects of SQ29548 on 8-epiPGF2K mediated ERK and
JNK activation in ULTR cells compared to
HEK.TPK10/L3 cells, our data also indicate that
8-epiPGF2K signals through another receptor, other
than SQ29548 sensitive TPs, in ULTR cells possibly
through a related prostanoid/eicosanoid receptor or
through a speci¢c 8-epiPGF2K receptor expressed in
the human SMCs, as previously alluded to by others
[25].
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